Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alecta Pensionsforsakring, Omsesidigt, managed by Magnus Billing, recently executed a significant transaction involving Eli Lilly And Company ((LLY)). The hedge fund reduced its position by 99,300 shares.
Recent Updates on Eli Lilly And Company stock
In recent days Eli Lilly (LLY) has issued a series of pipeline updates across obesity, oncology, cardiometabolic, and neurology, all signaling active R&D momentum rather than immediate earnings impact. The company completed a Phase 1 obesity trial of eloralintide (alone and with tirzepatide), which, if safety and exposure data are positive, could underpin a next wave of combination weight‑loss therapies and reinforce Lilly’s lead over rivals like Novo Nordisk. In oncology, a Phase 1/2 trial of BTK inhibitor pirtobrutinib (LOXO‑305) in CLL/SLL and NHL has also been completed and recently updated, a key de‑risking step that could support future market entry against incumbents Imbruvica and Calquence. Lilly is pushing its oral GLP‑1–class asset orforglipron into a large Phase 3 cardiovascular‑outcomes trial in patients with atherosclerotic cardiovascular disease and/or chronic kidney disease, aiming to extend its metabolic franchise into long‑term heart and kidney protection, while early‑stage work on LY4064809/STX‑478 and a completed delivery‑device study for Alzheimer’s drug remternetug highlight continued investment in next‑generation metabolic and neurology assets. The articles do not specify short‑term price moves, but collectively these updates are mildly positive for sentiment by underscoring breadth and progression of Lilly’s pipeline.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
The score is driven primarily by strong profitability and upbeat 2026 guidance (large projected revenue/EPS growth and continued product/pipeline momentum). Offsetting factors are weak cash-flow metrics and high leverage, while technicals are currently bearish and valuation remains expensive with a low dividend yield.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly And Company
YTD Price Performance: 3.02%
Average Trading Volume: 3,422,927
Current Market Cap: $1046.7B